Companies Dominating the Moyamoya Disease Landscape
- Abbott Laboratories
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck & Co., Inc.
- Siemens Healthcare GmbH
- Boston Scientific Corporation
- Johnson & Johnson Services, Inc.
- Valenta Pharmaceuticals Company
- Novartis AG
- Sanofi-Aventis Groupe
- AbbVie Inc.
- Elli Lilly and Company
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of moyamoya disease is assessed at USD 1.46 billion.
The moyamoya disease market size was valued at USD 1.39 billion in 2024 and is likely to cross USD 2.89 billion by 2037, registering more than 5.8% CAGR during the forecast period i.e., between 2025-2037. Increasing cases of moyamoya disease, and more people opting for medications over surgery will fuel the market growth.
North America industry is poised to account for largest revenue share of 33% by 2037, impelled by development of novel and cutting-edge technology in the region.
The major players in the market are Merck & Co., Inc., Siemens Healthcare GmbH, Boston Scientific Corporation, Johnson & Johnson Services, Inc., Valenta Pharmaceuticals Company, Novartis AG, Sanofi-Aventis Groupe, AbbVie Inc., Elli Lilly and Company, and others.
